Climb Bio, Inc. (CLYM) Tops Q2 EPS by 5c

Climb Bio, Inc. (NASDAQ: CLYM) reported Q2 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Climb Bio, Inc. (CLYM) click here.

You May Also Be Interested In

• Rockstar Energy founder seeks CEO role at Celsius Holdings
• King Pharmaceuticals (KG) Misses Q2 EPS by 103c
• Atlassian results seen as 'game changer' for AI kills software worries